Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma
Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma
复制标题
DOI：
10.1080/00016489.2019.1683604
复制
发表时间：
2020-01-14
影响因子：
1.4
通讯作者：
Hirose, Yoshinobu
中科院分区：
文献类型：
--
作者：
Higashino, Masaaki;Kawata, Ryo;Hirose, Yoshinobu
背景：免疫检查点配体程序性死亡配体1（PD-L1）在各种癌症中表达，包括头颈部癌症。然而，PD-L1的作用仍然未知。目的：探讨PD-L1在腮腺癌中的表达与生存率的关系。方法：采用免疫组化法检测127例腮腺癌组织中PD-L1的表达。评估PD-L1表达与分期、组织学分级和生存率之间的关系。结果如下：PD-L1在28.3%的腮腺癌中表达，在较高分期、较高级别和淋巴结阳性病例中表达较高。然而，PD-L1阳性患者的5年疾病特异性生存率为82.2%，PD-L1阴性患者为86.9%，无显著差异。结论：PD-L1表达在约50%的高级别癌中呈阳性，这与头颈部鳞状细胞癌中的水平相似。在其他癌症患者中，据报道，抗PD-1单克隆抗体对PD-L1表达较高的肿瘤更有效。因此，它可能是一种新的治疗选择，高度恶性腮腺肿瘤的患者，预后不良。
Background: The immune checkpoint ligand programmed death ligand-1 (PD-L1) is expressed by various cancers, including those of the head and neck. However, the role of PD-L1 is still unknown. Objectives: To investigate the relationship between PD-L1 expression and survival rate in parotid carcinoma. Methods: PD-L1 expression was investigated by immunohistochemical analysis in 127 patients with parotid carcinoma. The relationship between PD-L1 expression and stage, histological grade, and survival was assessed. Results: PD-L1 expression was found in 28.3% of parotid carcinomas, with the expression being higher in tumors with a higher stage, a higher-grade, and node positive cases. However, the 5-year disease-specific survival rate was 82.2% for the patients with PD-L1 positive and 86.9% for those with PD-L1 negative tumors, showing no significant difference. Conclusions: PD-L1 expression was positive in approximately 50% of high- grade carcinomas, which was similar to the level in head and neck squamous cell carcinoma. In patients with other cancers, it has been reported that an anti-PD-1 monoclonal antibody was more effective against tumors with higher PD-L1 expression. Therefore, it could be a possible new therapeutic option for patients with highly malignant parotid tumors that have a poor prognosis.